Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer: Long-term Outcomes From a Phase 1 Study

IMPORTANCE: Atezolizumab (anti–programmed death ligand 1) has demonstrated safety and activity in advanced and metastatic urothelial carcinoma, but its long-term clinical profile remains unknown. OBJECTIVE: To report long-term clinical outcomes with atezolizumab therapy for patients with metastatic...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Petrylak, Daniel P., Powles, Thomas, Bellmunt, Joaquim, Braiteh, Fadi, Loriot, Yohann, Morales-Barrera, Rafael, Burris, Howard A., Kim, Joseph W., Ding, Beiying, Kaiser, Constanze, Fassò, Marcella, O’Hear, Carol, Vogelzang, Nicholas J.
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5885219/
https://ncbi.nlm.nih.gov/pubmed/29423515
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2017.5440
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars